Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $152.59 million. The enterprise value is $118.25 million.
Important Dates
The last earnings date was Thursday, March 12, 2026, after market close.
| Earnings Date | Mar 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 14.42 million shares outstanding. The number of shares has increased by 5.32% in one year.
| Current Share Class | 14.42M |
| Shares Outstanding | 14.42M |
| Shares Change (YoY) | +5.32% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | 37.90% |
| Float | 9.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 25.02 |
| Forward PS | 78.07 |
| PB Ratio | 2.06 |
| P/TBV Ratio | 3.11 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 18.50 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.90, with a Debt / Equity ratio of 0.85.
| Current Ratio | 6.90 |
| Quick Ratio | 6.38 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -110.70% and return on invested capital (ROIC) is -36.38%.
| Return on Equity (ROE) | -110.70% |
| Return on Assets (ROA) | -32.14% |
| Return on Invested Capital (ROIC) | -36.38% |
| Return on Capital Employed (ROCE) | -85.99% |
| Weighted Average Cost of Capital (WACC) | 14.32% |
| Revenue Per Employee | $110,207 |
| Profits Per Employee | -$2.02M |
| Employee Count | 58 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $637,000 in taxes.
| Income Tax | 637,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.13% in the last 52 weeks. The beta is 2.54, so Korro Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.54 |
| 52-Week Price Change | -55.13% |
| 50-Day Moving Average | 11.33 |
| 200-Day Moving Average | 18.73 |
| Relative Strength Index (RSI) | 43.58 |
| Average Volume (20 Days) | 236,800 |
Short Selling Information
The latest short interest is 1.04 million, so 7.23% of the outstanding shares have been sold short.
| Short Interest | 1.04M |
| Short Previous Month | 1.07M |
| Short % of Shares Out | 7.23% |
| Short % of Float | 10.88% |
| Short Ratio (days to cover) | 4.05 |
Income Statement
In the last 12 months, Korro Bio had revenue of $6.39 million and -$117.26 million in losses. Loss per share was -$12.48.
| Revenue | 6.39M |
| Gross Profit | -48.74M |
| Operating Income | -87.34M |
| Pretax Income | -116.62M |
| Net Income | -117.26M |
| EBITDA | -83.06M |
| EBIT | -87.34M |
| Loss Per Share | -$12.48 |
Full Income StatementBalance Sheet
The company has $75.16 million in cash and $43.49 million in debt, with a net cash position of $41.70 million or $2.89 per share.
| Cash & Cash Equivalents | 75.16M |
| Total Debt | 43.49M |
| Net Cash | 41.70M |
| Net Cash Per Share | $2.89 |
| Equity (Book Value) | 51.44M |
| Book Value Per Share | 5.46 |
| Working Capital | 70.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$78.56 million and capital expenditures -$518,000, giving a free cash flow of -$79.08 million.
| Operating Cash Flow | -78.56M |
| Capital Expenditures | -518,000 |
| Depreciation & Amortization | 4.28M |
| Net Borrowing | n/a |
| Free Cash Flow | -79.08M |
| FCF Per Share | -$5.48 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,366.43% |
| Pretax Margin | -1,824.52% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.32% |
| Shareholder Yield | -5.32% |
| Earnings Yield | -73.31% |
| FCF Yield | -49.44% |
Analyst Forecast
The average price target for Korro Bio is $34.80, which is 228.92% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.80 |
| Price Target Difference | 228.92% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 40.02% |
| EPS Growth Forecast (5Y) | 1.90% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -4.44 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.44 |
| Piotroski F-Score | 3 |
